论文部分内容阅读
目的:探讨细胞GRIM-19在膀胱癌组织中的表达及与病理分级和临床分期之间的关系。方法:采用Westernblot方法分别检测50例膀胱癌患者膀胱癌组织、癌旁组织及38例正常膀胱组织中GRIM-19的表达情况,进行分析上述指标与膀胱癌病理分级和临床分期的关系。结果:显示GRIM-19膀胱癌、癌旁组织中的表达与正常膀胱组织比较,差异有统计学意义(P<0.01),膀胱癌、癌旁组织中的表达比较,差异具有统计学意义(P<0.05)。膀胱癌、癌旁组织中的表达:临床分级,Ⅰ级逐渐向Ⅲ级下降,差异具有统计学意义(P<0.01);临床分期,T2～T4高于Tis～T1,差异具有统计学意义(P<0.01);是否转移,转移比未转移的表达量低,差异具有统计学意义(P<0.01)。GRIM-19蛋白在病理分级、临床分期及中是否转移的表达情况,均呈正相关。结论:GRIM-19可以作为判定膀胱癌的预后的一个标准。
OBJECTIVE: To investigate the relationship between the expression of GRIM-19 in bladder cancer and the pathological grade and clinical stage. Methods: The expression of GRIM-19 in bladder cancer tissues, paracancerous tissues and 38 normal bladder tissues from 50 cases of bladder cancer was detected by Western blot. The relationship between the above indexes and the pathological grade and clinical stage were analyzed. Results: The expression of GRIM-19 in bladder cancer and paracancerous tissues was significantly higher than that in normal bladder tissues (P <0.01), and the difference was statistically significant (P <0.05). (P <0.01). The clinical stage, T2 ~ T4 were higher than Tis ~ T1, the difference was statistically significant (P < P <0.01). The metastasis and metastasis were lower than those without metastasis, the difference was statistically significant (P <0.01). GRIM-19 protein in the pathological grade, clinical stage and whether the expression of metastasis, were positively correlated. Conclusion: GRIM-19 can be used as a criterion to judge the prognosis of bladder cancer.